Overview

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
Phase:
Phase 3
Details
Lead Sponsor:
Tolmar Inc.
Treatments:
Leuprolide